Section Review: Biologicals & Immunologicals: Development of prodrugs for ADEPT (antibody-directed enzyme prodrug therapy)

References

• JARMAN M: The development of anticancer drugs. Chem-istry in Britain (1989) 25:51–54.
   Google Scholar
• NICULESCU-DUVAZ I, BARACU I, BALABAN AT: In: Chem-istry of Antitumour Agents. Wilman DEV (Ed.), Blackie, London (1990):63–131.
   Google Scholar
• BAGSHAWE K.D, SPRINGER CJ, SEARLE F, ANTONIW P, SHARMA SK, MELTON RG, SHERWOOD RF: A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer (1988) 58:700–703.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE KD: Antibody directed enzymes revive anti-cancer prodrug concept. Br. J. Cancer (1987) 56:531–532.
   PubMed Web of Science ®Google Scholar
• SENTER PD, SU PCD, KATSURAGI T, SAKAI T, COSAND WL, HELLSTROM I, HELLSTROM KE: Generation of 5-fluorouracll from 5-fluorocytosine by monoclonal an-tibody-cytosine deaminase conjugates. Bioconj. Chem. (1991) 2:447–451.
   PubMed Web of Science ®Google Scholar
• WALLACE PM, MACMASTER JF, SMITH VF, KERR DE, SEN-TER PD, COSAND WL: Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocy-tosine. Cancer Res. (1994) 54:2719–2723.
   PubMed Web of Science ®Google Scholar
• SENTER PD, SAULNIER MG, SCHREIBER GJ, HIRSHBERGDL, BROWN JP, HELLSTROM I, HELLSTROM IcE: Anti-tu-mor effects of antibody-alkaline phosphatase conju-gates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA (1988) 85:4842–4846.
   PubMed Web of Science ®Google Scholar
• SAHIN U, HARTMANN F, SENTER PD, POHL C, ENGERT A, DHIEL V, PFREUNDSCHUH M: Specific activation of the prodrug mitomycin phosphate by a bispecific ant1-CD3O/ anti- alkaline phosphatase monoclonal anti-body. Cancer Res. (1990) 50:6944–6948.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE K.D, SHARMA SK, SPRINGER CJ, ROGERS GT: Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A review of some theoretical, experimental and clinical aspects. Anal. Oncol. (1994) 5:879–891.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE KD, SHARMA SK, SPRINGER CJ, ANTONIW P: Antibody-directed prodrug therapy (ADEPT): a pilot scale clinical therapy. Tumor Targeting (1995) 1:17–29.
   Google Scholar
• BAGSHAWE ICD, SHARMA SK, SPRINGER CJ, ANTONIW P, BODEN JA, ROGERS GT, BURKE PJ, MELTON RG, SHER-WOOD RF: Antibody-Directed Enzyme Prodrug Therapy (ADEPT): Clinical report. Disease Markers (1991) 9:233–238.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE 1(1), SHARMA SK, SPRINGER CJ, ANTONIW P,ROGERS GT, BURKE PJ, MELTON R, SHERWOOD R: Anti-body-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibody, Im-munoconjugates and Radiopharmaceuticals (1991) 4:915–922.
   Google Scholar
• SEDLACEK HH, SEEMANN G, HOFFMANN D, CZECH J, LORENZ P, KOLAR C, BOSSLET K: Antibodies as Carriers of Cytotoxicity. Karger, Basel (1992):208.
   Google Scholar
• SENTER PD, WALLACE PM, SVENSSON HP, VRUDHULA VM, KERR DE, HELLSTROM I, HELLSTROM ICE: Generation of cytotoxic agents by targeted enzymes. Bioconj. Chem. (1993) 4:3–9.
   PubMed Web of Science ®Google Scholar
• DEONARAIN MP, EPENETOS AA: Targeting enzymes for cancer therapy: old enzymes in new roles. Br.], Cancer (1994) 70:786–794.
   PubMed Web of Science ®Google Scholar
• NICULESCU-DUVAZ I, SPRINGER CJ: Antibody-directed enzyme prodrug therapy (ADEPT): a targeting strategy In cancer chemotherapy. Curr. Med. Chem. (1995). In press.
   Google Scholar
• SPRINGER CJ, NICULESCU-DUVAZ I: Antibody-directed enzyme prodrug therapy (ADEPT) with mustard pro-drugs. Anti-Cancer Drug Design (1995) 10:361–372.
   PubMedGoogle Scholar
• JUNGHEIM LN, SHEPHERD TT: Design of antitumor pro-drugs: substrates for antibody targeted enzymes. Chem. Rev. (1994) 94:1553–1566.
   Web of Science ®Google Scholar
• HAISMA HJ, BOVEN E, VAN MUIJEN M, DE JONG J, VAN DER VYGH VVJF, PINEDO HM: A monoclonal antibody-13-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for the specific treatment of cancer. Br.]. Cancer (1992) 66:474–478.
   PubMed Web of Science ®Google Scholar
• SENTER PD: Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy. FASEB J. (1990) 4:188–193.
   PubMed Web of Science ®Google Scholar
• MEYER DL, jUNGHEIM LN, MIKOLAJCZYK SD, SHEPHERD TA, STARLING JJ, AHLEM C: Preparation and charac-terization of j3-lactamase-Fab' conjugates for the site specific activation of oncolytic agents. Bioconj. Chem. (1992) 3:42–48.
   PubMed Web of Science ®Google Scholar
• BOSSLET K, CZECH J, SEEMAN G, MONNERET C, HOFF-MANN D: Fusion protein mediated prodrug activation (FMPA) in vivo. Cell Biophys. (1994) 24/25:51–63.
   Google Scholar
• BOSSLET K, CZECH J, HOFFMANN D: Tumor-selective prodrug activation by fusion protein-mediated cataly-sis. Cancer Res. (1994) 54:2151–2159.
   PubMed Web of Science ®Google Scholar
• MIYASHITA H, KARAKI Y, KINICHI M, FUJII I: Prodrug activation via catalytic antibodies. Proc. Natl. Acad. Sci. USA (1993) 90:5337–5340.
   PubMed Web of Science ®Google Scholar
• WARD BG, MATHER SJ, HAWKINS LR, CROWTHER ME, SHEPHERD JH, GRANOWSKA M, BRITTON ICE, SLEVIN ML: Localization of radioiodine conjugated to the mono- clonal antibody IIMGF-2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. Cancer Res. (1987) 47:4719.
   PubMed Web of Science ®Google Scholar
• MALAMITSI J, SKARLOS D, FOTIOU S, PAPAKOSTAS J,ARAVANTINOS G, VASSILARU D, TAYLOR-PA-PADIMITRIOU J, KOUTOULIDIS 5, HOOKER G, SNOOK D, EPENETOS AA: Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. J. Nucl. Med. (1988) 29:1910–1915.
   PubMed Web of Science ®Google Scholar
• ROGERS GT, PEDLEY RB, SODEN J, HARWOOD PJ, BAG-SHAWE KD: Effect of dose escalation of a monockmal anti-CEA-IgG on tumour localisation and tissue distri-bution in nude mice xenografted with human colon carcinoma. Cancer Immunol. Immunot her. (1986) 23:107.
   PubMed Web of Science ®Google Scholar
• SCOTT WILBUR D: An overview of radionuclides, label-ing methods and reagent for conjugate labelling. Bio-conj. Chem. (1992) 3:433–470.
   Google Scholar
• SCOTT WILBUR D, STRAY JE, HAMLIN DK, CURTIS DK, VESSEL1A RL: Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer allcylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(abl2 fragments. Bioconj. Chem. (1994) 5:220–235.
   Google Scholar
• JAIN RK, BAXTER LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other mac-romolecules in tumors: Significance of elevated inter-stitial pressure. Cancer Res. (1988) 48:7022–7032.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Physiological barriers to delivery of mono-clonal antibodies and others macromolecules in tu-mors. Cancer Res. (1990) 50:814s–819s.
   Google Scholar
• SWAB EA, WEI J, GULLINO PM: Diffusion and convectionIn normal and neoplastic tissues. Cancer Res. (1974) 34:2814–2822.
   PubMed Web of Science ®Google Scholar
• STELLA VG, HIMMELSTEIN KJ: Prodrugs and site-specific drug delivery. J. Med. Chem. (1980) 23:1275–1282.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Transport of molecules in the tumor intersti-tium: A review. Cancer Res. (1987) 47:3039–3051.
   PubMed Web of Science ®Google Scholar
• CONNORS TA: Antitumor drugs with latent activity. Biochemie (1978) 60:979–987.
   Web of Science ®Google Scholar
• CARL PL, CHAKRAVARTY PK, KATZENELLENBOGEN JA: A novel connector linkage applicable in prodrug design. J. Med. Chem. (1981) 24:479–480.
   PubMed Web of Science ®Google Scholar
• SENTER PD, PEARCE WE, GREENFIELD RS: Development of a drug-release strategy based on the reductive frag-mentation of benzyl carbamate disulfides. J. Org. Chem. (1990) 55:2975–2978.
   Web of Science ®Google Scholar
• IZAWA T, KATO K: Design and synthesis of an antitumor prodrug released by the reaction with sulfhyclryl com-pounds. Bioorg. Med. Chem. (1995) 5:593–596.
   Web of Science ®Google Scholar
• YUAN J, BAXTER LT, JAIN RK: Pharmacolcinetic analysis of two-step approaches using bifunctional and enzyme-conjugate antibodies. Cancer Res. (1991) 51:3119–3130.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ: CMDA, an antineoplastic prodrug. Drugs of the Future (1993) 18:212–215.
   Google Scholar
• SPRINGER CJ, NICULESCU-DUVAZ I, MAUGER AB, CON-NORS TA, BURKE PJ, DAVIES DH, DOWELL RI, BOYLE FT, BLAKEY DC, MELTON RG: In: New Antibody Technology and the Emergence of Useful Cancer Therapy. Begent R, Hamlin A (Eds.), The Royal Society of Medicine Press, London (1995):75–77.
   Google Scholar
• MANN J, HAASE-HELD M, SPRINGER CJ, BAGSHAWE KID:Synthesis of an N-mustard prodrug. Tetrahedron (1990) 46:5377–5382.
   Web of Science ®Google Scholar
• SPRINGER CJ, ANTONIW P, BAGSHAWE KD, SEARLE F, BISSET GMF, JARMAN M: Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypep-tidase G2. J. Med. Chem. (1990) 33:677–681.
   PubMed Web of Science ®Google Scholar
• NICULESCU-DUVAZ I, PEDLEY RB, SPRINGER CJ: New prodrugs for antibody-directed enzyme prodrug ther-apy. Proceedings of the UICC International Cancer Congress (1994) 4:2779–2782.
   Google Scholar
• BAGSHAWE KD: Toward generating cytotoxic agents at cancer sites. Br. J. Cancer (1989) 60:275–281.
   PubMed Web of Science ®Google Scholar
• FRET E, TEICHER BA, HOLDEN SA: Preclinical studies and clinical correlation of the effect of alkylating drugs. Cancer Res. (1988) 48:6417.
   PubMed Web of Science ®Google Scholar
• DU FRAIN RJ, LITTLEFIELD LG, WILMER JL: Cydophos-phamide induced SCEs in rabbit lymphocytes. Environ-mental Mutagenesis (1979) 1:283–289.
   PubMedGoogle Scholar
• TEICHER BA, FREI III E: Development of alkylating agent resistant human tumor cell lines. Cancer Chemother. Pharmacol. (1988) 21:292–298.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, ANTONIW P, BAGSHAWE KD, WILMANDEV: Comparison of half-lives and cytotoxicity of N-mesy-loxyethyl- and N-chloroethy1-4-amino benzoyl com-pounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug De-sign (1991) 6:467–479.
   PubMedGoogle Scholar
• SPRINGER CJ, NICULESCU-DUVAZ I, PEDLEY RB: Novel prodrugs of alkylating agents derived from 2-fluoro-and 3-fluoro benzoic adds for antibody-directed en-zyme prodrug therapy. J. Med. Chem. (1994) 37:2361–2370.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, BLAKEY DC, MAUGER AG, NICULESCU-DU-VAZ I, BURKE PJ, DAVIES DH, DOWELL RI, MELTON EM: A novel bis-iodo phenol mustard prodrug for antibody-directed enzyme prodrug therapy (ADEPT). Proceedings of the 11th International Hammersmith Meeting - Advances in Applications of Monoclonal Antibodies in Clinical Oncol-ogy. Lesbos, Greece (1994):41.
   Google Scholar
• SPRINGER CJ, NICULESCU-DUVAZ I, EAST CJ, DOWELL RI, DAVIES DM, BURKE PD, MELTON RG, BLAKEY DC: A new clinical candidate for Antibody-directed enzyme pro-drug therapy (ADEPT), ZD 2767. Proceedings of the 8th AEK Symposium. Heidelberg (1995).
   Google Scholar
• SPRINGER CJ, BAGSHAWE KD, SHARMA SK, SEARLE F, BODEN JA, ANTONIW P, BURKE PJ, ROGERS GT, SHER-WOOD RF, MELTON RG: Ablation of human choriocar-cinoma xenografts in nude mice by Antibody-Directed Enzyme Prodrug Therapy (ADEPT) with three novel compounds. Eur. J. Cancer (1991) 27:1361–1366.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BODEN JA, SPRINGER CJ, BURKE PJ, BAG-SHAWE KD: Antibody-directed prodrug therapy (ADEPT). A three-phase study in ovarian tumour xenografts. Cell Biophys. (1994) 24/25:219–228.
   Google Scholar
• ECCLES S, COURT WJ, BOX GA, DEAN CJ, MELTON RG, SPRINGER CJ: Regression of established breast carci-noma xenografts with antibody-directed enzyme pro-drug therapy against C-erbB2 p185. Cancer Res. (1994) 54:5171–5177.
   PubMed Web of Science ®Google Scholar
• ANTONIW P, SPRINGER CJ, BAGSHAWE 1(1), SEARLE F, MELTON RG, ROGERS GT, BLTRKE PJ, SHERWOOD RF: Disposition of the prodrug 44bis(2-chlo- roethyfiamintAbenzoyl-L-ghttamic acid and its active parent drug in mice. Br. J. Cancer (1990) 62:909–914.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, ANTONIW P, BAGSHAWE KID: In: Monoclonal Antibodies-Applications in Clinical Oncology (Volume 1). Epenetos AA (Ed.), Chapman & Hall, London (1991):185–191.
   Google Scholar
• SHARMA SK, BAGSHAWE ICD, BURKE PJ, BODEN JA, RO-GERS GT, ANTONIW P, SPRINGER CJ, MELTON RG, SHER-WOOD RF: Galactosylated antibodies and antibody-enzyme conjugates in ADEPT. Cancer (1994) 73:1114–1120.
   PubMed Web of Science ®Google Scholar
• NICULESCU-DUVAZ I, SPRINGER CJ: Adamantylanyloxy-carbonyl: a novel protecting group for phenols carry-ing strongly electron-withdrawing substituents. J. Chem. Research (1994) SuppL : 24 2–243.
   Google Scholar
• SPRINGER CJ, DOWELL RL, BURKE PJ, HADLEY E, DAVIES DH, BLAKEY DC, MELTON RG, NICULESCU-DUVAZ I: Op-timization of alkylating agents prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for ADEPT. J. Med. Chem. (1995) 38:5051–5065.
   PubMed Web of Science ®Google Scholar
• BLAKEY DC, SPRINGER CJ, MAUGER AG, DAVIES DH, DOWELL RI, EAST SJ, BURKE PJ, MELTON RG: Tumour regressions caused by a bisiodo-phenol mustard pro-drug in antibody-directed enzyme prodrug therapy (ADEPT). Proceedings of the 11th International Ham-mersmith Meeting - Advances in Applications of Monoclonal Antibodies in Clinical Oncology. Lesbos, Greece (1994):42.
   Google Scholar
• WALLACE PM, SENTER PD: In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conju-gates in combination with phenol mustard phosphate. Bioconj. Chem. (1991) 2:349–352.
   PubMed Web of Science ®Google Scholar
• ROFFLER SR, WANG SM, CHERN JW, YEH MY, TUNG E: Anti-neoplastic glucuronide prodrug treatment of hu-man tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem. Pharmacol. (1991) 42:2062–2065.
   PubMed Web of Science ®Google Scholar
• WANG SM, CHERN JW, YEH MY, NG JC, TUNG E, ROFFLERSR: Specific activation of glucuronide prodrugs by anti-body-targeted enzyme conjugates for cancer therapy. Cancer Res. (1992) 52:4484–4491.
   PubMed Web of Science ®Google Scholar
• ALEXANDER RP, BEELEY NRA, O'DRISCOLL M, O'NEIL FP, MILLIGAN TA, PRATT AJ, WILLENBROCK FW: Cepha-losporin nitrogen mustard carbamate prodrugs for 'ADEPT'. Tetrahedron Lett. 1991, 32, 3269–3272.
   Web of Science ®Google Scholar
• SVENSSON HP, KADOW JF, VRUDHULA VM, WALLACE PM, SENTER PD: Monoclonal antibody-f3-lactamase conju-gates for the activation of a cephalosporin mustard prodrug. Bioconj. Chem. (1992) 3:176–181.
   PubMed Web of Science ®Google Scholar
• SVENSSON HP, WALLACE PM, SENTER PD: Synthesis and characterisation of monoclonal antibody-13-lactamase conjugates. Bioconj. Chem. (1994) 5:262–267.
   PubMed Web of Science ®Google Scholar
• HANESSIAN S, WANG J: Design and synthesis of a cepha-losporin-carboplatinum prodrug activatable by a II-lac-tamase. Can. J. Chem. (1993) 71:896–906.
   Web of Science ®Google Scholar
• JUNGHEIM LN, SHEPHERD TA, MEYER DL: Synthesis of acylhydrazido-substituted cephems. Design of cepha-losporin-vinca alkaloid prodrugs : substrates for an antibody-targeted enzyme. J. Org. Chem. (1992) 57:2334–2340.
   Google Scholar
• ICERR DE, SCHREIBER GJ, VRUDHULA VM, SVENSSON HP,HELLSTROM I, HELLSTROM ICE, SENTER PD: Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates In combination with anticancer prodrugs. Cancer Res. (1995) 55:3358–3363.
   Google Scholar
• VRUDHULA VM, SVENSSON HP, SENTER PD: Cepha-losporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-I3-lactamase conju-gates. J. Med. Chem. (1995) 38:1380–1385.
   PubMed Web of Science ®Google Scholar
• COBB LM, CONNORS TA, ELSON LA, KHAN AH, MIT-SCHLEY BVC, ROSS WCJ, WHISSON ME: 2,4-Diaitro-5-ethyleneiminobenzamide (CB1954): a potent and selective inhibitor of growth of the Walker carcinoma 256. Biochem. Pharmacol. (1969) 18:1519–1527.
   PubMed Web of Science ®Google Scholar
• ROBERTS JJ, FRIEDLOS F, KNOX RJ: CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes an DNA interstrand crosslinking agent in Walker tumour cells. Biochem. Biophys. Res. Commun. (1986) 140:1073–1078.
   Google Scholar
• KNOX RJ, FRIEDLOS F, BIGGS PJ, FLITER WD, GASKELL M, GODDARD P, DAVIES L, JARMAN M: Identification, syn-thesis and properties of 5-(aziridin-l-y1)-2-nitro-4-ni-trosobenzataide, a novel DNA cross-linking agent derived from CB 1954. Biocheni. Pharmacol. (1993) 46:797–803.
   PubMed Web of Science ®Google Scholar
• DAVIES LC: Simple synthesis of the 5-0-benzoylriboside of 1,4-dihydronicotinic acid: a cofactor for DT dia-phorase and nitroreductase enzymes. Nucleosides and Nucleotides (1995) 14:311–312.
   Google Scholar
• SOMANI HH, WILMAN DEV: Novel analogues of CB 1954:their potential use in Antibody Directed Enzyme Ther-apy. Eur. J. Cancer (1994) 30A:9.
   Google Scholar
• ANLEZARK GM, MELTON RG, SHERWOOD RF, WILSON WR, DENNY WA, PALMER BD, KNOX RJ, FRIEDLOS F, WILLIAM A: Bioactivation of dinitrobenzamide mustards by an Escherichia coil-B nitroreductase. Biochern. Phar-macol. (1995) 50:609–618.
   PubMed Web of Science ®Google Scholar
• MAUGER AB, BURKE PJ, SOMANI HFI, FRIEDLOS F, KNOXRJ: Self-immolative prodrugs: Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. (1994) 37:3452–3458.
   PubMed Web of Science ®Google Scholar
• KERR DE, SENTER PD, BURNETT PD, HIRSCHBERG DL,HELLSTROM I, HELLSTROM ICE: Antibody-penicillin-V-arniriase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamith. Cancer Immunol. Immunother. (1990) 31:202–206.
   PubMed Web of Science ®Google Scholar
• KUEFNER U, LOHRMANN U, MONTEJANO YD, VITOLS KS,HUENNEKENS FM: Carboxypeptidase-mediated release of methotrexate from methotrexate-a-peptides. Bio-chemistry (1989) 28:2288–2297.
   Google Scholar
• VITOLS KS, MONTEJANO Y, KUEFNER U, HUENNEKENS FM: Selective cytotoxicity of carboxypeptidase-acti-vated methotrexate a-peptides. Pteridines (1989) 1:65–70.
   Google Scholar
• VITOLS KS, HAENSELER E, MONTEJANO Y, BAER T, HUEN-NEKENS, FM: In: Pteridines (Volume 3). Curtius H-C, Ghisla S, Blau N (Eds.), Walter de Gruyer, Berlin (1992):125–126.
   Google Scholar
• HAENSELER E, ESSWEIN A, VITOLS KJ, MONTEJANO Y, MUELLER BM, REISFELD RA, HUENNEKENS MF: Activation of methotrexate-a-alanine by carboxypeptidase monoclonal antibody conjugate. Biochemistry (1992) 31:891–897.
   PubMed Web of Science ®Google Scholar
• HUENNEKENS FM: Tumor targeting: activation of pro-drugs by enzyme-monoclonal antibody conjugates. Trends in Biotechnology (1994) 12:234–239.
   PubMed Web of Science ®Google Scholar
• VITOLS KS, HAAG-ZEINO B, BAER T, MONTEJANO YD,HUENNEKENS FM: Methotrexate-a-phenylalanine: opti-mization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody. Cancer Res. (1995) 55:478–481.
   PubMed Web of Science ®Google Scholar
• ABRAHAM R, AMAN N, VON BORSTEL R, DARSLEY M, KAMIREDDY B, KENTEN J, MORRIS G, TITMAS R: Conju-gates of COL-1 monoclonal antibody and fl-galactosi-dase can specifically kill tumor cells by generation of 5-flourouridine from the prodrug 13-D-galactosy1-5-fluorouridine. Cell Biophys. (1994) 24/25:127–133.
   Google Scholar
• CHABNER BA: In: Cancer Chemotherapy and Biological Response Modifiers (Volume 13). Pinedo HM, Longo DL, Chabner BA (Eds.), Elsevier, Amsterdam, London, New York, Tokyo (1992):69–74.
   Google Scholar
• CHABNER BA: In: Cancer Chemotherapy and Biological Response Modifiers (Volume 15). Pined° HM, Longo DL, Chabner BA (Ed.), Elsevier, Amsterdam, London, New York, Tokyo (1994):58–67.
   Google Scholar
• LIU LF: Topoisomerase poisons as antitumor drugs. Ann. Rev. Biochem. (1989) 58:351–375.
   PubMed Web of Science ®Google Scholar
• ROWLINSON-BUSZA G, BAMIAS A, KRAUSZ T, EVANS DJ, EPENETOS AA: In: Monoclonal Antibodies. Application in Clinical Oncology (Volume 1). Epenetos AA (Ed.), Chapman & Hall, London (1991):179–184.
   Google Scholar
• ROWLINSON-BUSZA G, BAMIAS A, KRAUSZ T, EPENETOSAA: In: Monoclonal Antibodies. Application in Clinical On-cology (Volume 2). Epenetos AA (Ed.), Chapmann and Hall, London (1992):111–118.
   Google Scholar
• SVENSSON HP, VRUDHULA VM, EMSWILER JE, MACMAS-TER JF, COSAND WL, SENTER PD, WALLACE PM: In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody 0-lactamase conjugates. Cancer Res. (1995) 55:2357–2363.
   PubMed Web of Science ®Google Scholar
• SENTER PD, SVENSSON HP, SCHREIBER GJ, RODRIGUEZJL, VRUDHULA VM: Poly(ethylene glycol)-doxorubicin conjugates containing 13-lactamase-sensitive linkers. Bioconj. Chem. (1995) 6:389–394.
   PubMed Web of Science ®Google Scholar
• ANDRIANOMENJANAHARY S, DONG X, FLORENT JC, GAUDEL G, GESSON JP, JACQUESY JC, KOCH M, MICHEL S, MONDON M, MONNERET C, PETIT P, RENOUX B, TILLEQUIN F: Synthesis of novel targeted pro-drugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate (Part 1). Bioorg. Med. Chem. Let t. (1992) 2:1093–1096.
   Web of Science ®Google Scholar
• GESSON JP, JACQUESY JC, MONDON M, PETIT P, RENOUXB, ANDRIANOMENJANAHARY S, VAN DUFAT-TRINH H, KOCH M, MICHEL S, TILLEQUIN F, FLORENT JC, MON-NERET C, BOSSLET K, CZECH J, HOFFMANN D: Prodrugs of anthracyclines for chemotherapy via enzyme-mono-clonal antibody conjugates. Anti-Cancer Drug Design (1994) 9:409–423.
   PubMedGoogle Scholar
• HAISMA HJ, VAN MUIJEN M, PINEDO HM, BOVEN E: Comparison of two anthracycline-based produgs for activation by a monoclonal antibody-0-g,lucuronidase conjugate in specific treatment of cancer. Cell Biophys. (1994) 24/25:185–192.
   Google Scholar
• JUNGHEIM LN, SHEPHERD TA, KLING JK: Synthesis of acephalosporin-doxorubicln antitumor prodrug: a sub-strate for an antibody-targeted enzyme. Heterocycles (1993) 35:339-348.90.
   Google Scholar
• HUDYMA TW, BUSH K, COLSON K, FIRESTONE RA, KING HD: Synthesis and release of doxorubicin from a cepba-losporin based prodrug by a 13-lactamase conjugate. Btoorg. Med. Chem. Lett. (1993) 3:323–328.
   Web of Science ®Google Scholar
• MEYER DL, LAW KL, PAYNE JK, MIKOLAJCZYK SD, ZAR-RINMAYEH H, JUNGHEIM LN, KLING JK, SHEPHERD TA, STARLING JJ: Site-specific drug activation by antibody-P-lactamase conjugates: Preclinical investigation of the efficacy and toxicity of doxorubicin delivered by anti-body directed catalysis. Bioconj. Chem. (1995) 6:440–446.
   PubMed Web of Science ®Google Scholar
• RODRIGUES ML, PRESTA LG, KOTTS CE, WIRTH C, MOR-DENTI C, OSAKA G, WONG WT, NUIJENS A, BLACKBURN B, CARTER P: Development of a humanized disulfide-sta-bilized anti-p185HER Fv-fl-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 1995, 55, 63–70.
   PubMed Web of Science ®Google Scholar
• VRUDHULA MV, SENTER PD, FISCHER K, WALLACE PM: Procirugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G ami-dase conjugate. J. Med. Chem. (1993) 36:919–923.
   PubMed Web of Science ®Google Scholar
• ICNOX RJ, FRLEDLOS F, SHERWOOD RF, MELTON RG, ANLEZARK GM: The bioactivation of 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB 1954). IL A comparison of an Escherichia coli nitroreductase and Walker DT-dia-phorase. Biochem. Pharmacol. (1992) 44:2297–2301.
   Google Scholar
• SENTER PD, SCHREIBER GJ, HIRSHBERG DL, ASHE SA, HELLSTROM RE, HELLSTROM I: Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antthody_aikaline phosphatase conjugates. Cancer Res. 1989, 49, 5789–5792.
   PubMed Web of Science ®Google Scholar
• HAISMA HJ, BOVEN E, VAN MUIJEN M, DE VRIES R, PINEDO HM: Analysis of a conjugate between anticarci-noembryonic antigen and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immmunol. Immunother, (1992) 34:343–348.
   PubMed Web of Science ®Google Scholar
• SHEPHERD TA, JUNGHEIM LN, MEYER DL, STARLING JJ: A novel targeted delivery system utilizing a cepha-losporin oncolytic prodrug activated by an antibody P-lactamase conjugate for the treatment of cancer. Bioorg. Med. Chem. Lett. (1991) 1:21–26.
   Web of Science ®Google Scholar
• MEYER DL, JUNGHEIM LN, LAW Tu., MIKOLAJCZYK SD, SHEPHERD TA, MACKENSEN DG, BRIGGS SL, STARLING JJ: Site-specific prodrug activation by antibody-P-lac-tatnase conjugates: regression and long-term growth Inhibition by human colon carcinoma xenograft mod-els. Cancer Res (1993) 53:3956–3963.
   Google Scholar
• RODRIGUES ML, CARTER P, WIRTH C, MULLINS S, LEE A, BLACKBURN BK: Synthesis and plactamase-mediated activation of a cephalosporin-taxol prodrug. Chemisuy & Biology (1995) 2:223–227.
   PubMed Web of Science ®Google Scholar
• BIGNANI GS, SENTER PD, GROTHAUS PG, FISCHER KJ, HUMPHREYS T, WALLACE PM: N-(4'-Hydroxyphenylace-tyfipalytoxin: A palytoxin prodrug that can be activated by a monoclonal antibody-penicillin-G amirlAse conju-gate. Cancer Res. (1992).
   Google Scholar
• HAY MP, WILSON WR, DENNY WA: A novel enediyne prodrug for antibody-directed enzyme prodrug ther-apy (ADEPT) using E. ColiB nitroreductase. Biomg. Med. Chem. (1995) 5:2829–2834.
   Web of Science ®Google Scholar
• WERLEN RC, LANKINEN M, ROSE K, BLAKEY D, SHUTTLE-WORTH H, MELTON R, OFFORD RE: Site specific conju-gation of an enzyme and an antibody fragment. Bioconj. Chem. (1994) 5:411–417.
   PubMed Web of Science ®Google Scholar